[1]王继芳,魏秀丽.氟达拉滨联合阿糖胞苷治疗急性髓系白血病疗效观察[J].新乡医学院学报,2018,35(3):204-206.[doi:10.7683/xxyxyxb.2018.03.011]
 WANG Ji-fang,WEI Xiu-li.Effect of fludarabine combined with cytarabine on acute myeloid leukemia[J].Journal of Xinxiang Medical University,2018,35(3):204-206.[doi:10.7683/xxyxyxb.2018.03.011]
点击复制

氟达拉滨联合阿糖胞苷治疗急性髓系白血病疗效观察
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年3
页码:
204-206
栏目:
临床研究
出版日期:
2018-03-05

文章信息/Info

Title:
Effect of fludarabine combined with cytarabine on acute myeloid leukemia
作者:
王继芳魏秀丽
(新乡市第一人民医院血液内科,河南 新乡 453000)
Author(s):
WANG Ji-fangWEI Xiu-li
(Department of Haematology,the First People′s Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China)
关键词:
急性白血病急性髓系白血病氟达拉滨阿糖胞苷
Keywords:
acute leukemiaacute myeloid leukemiafludarabinecytarabine
分类号:
R733.71
DOI:
10.7683/xxyxyxb.2018.03.011
文献标志码:
A
摘要:
目的 探讨氟达拉滨联合中剂量阿糖胞苷治疗急性髓系白血病(AML)的临床效果。方法 选择2011年1月至2016年1月新乡市第一人民医院收治的AML患者55例,其中初次诱导早期反应不良患者16例(双诱导组),初次诱导失败患者15例(初次诱导失败组),复发难治性患者24例(复发难治组),所有患者给予氟达拉滨和中剂量阿糖胞苷联合治疗,4周为1个疗程,治疗2个疗程后对3组患者的治疗效果及生存状况进行比较。结果 双诱导组、初次诱导失败组和复发难治组患者治疗总有效率分别为81.3%(13/16)、66.7%(10/15)、33.3%(8/24),双诱导组和初次诱导失败组患者治疗总有效率均显著高于复发难治组(χ2=8.839、4.127,P<0.05),双诱导组与初次诱导失败组患者治疗总有效率比较差异无统计学意义(χ2=0.860,P>0.05)。双诱导组、初次诱导失败组和复发难治组患者中位无病生存期分别为29、21、10个月,双诱导组患者中位无病生存期显著长于初次诱导失败组和复发难治组(χ2=9.536、33.256,P<0.05),初次诱导失败组患者中位无病生存期显著长于复发难治组(χ2=21.077,P<0.05)。双诱导组、初次诱导失败组和复发难治组患者中位总生存期分别为40、29、12个月,双诱导组和初次诱导失败组患者中位总生存期显著长于复发难治组(χ2=33.686、28.649,P<0.05),双诱导组与初次诱导失败组患者中位总生存期比较差异无统计学意义(χ2=2.417,P>0.05)。结论 氟达拉滨联合中剂量阿糖胞苷治疗AML疗效显著,对初次诱导早期反应不良和初次诱导失败患者的治疗效果优于复发难治患者。
Abstract:
Objective To investigate the effect of fludarabine combined with medium dose cytarabine on acute myeloid leukemia(AML).Methods A total of 55 AML patients were selected from January 2011 to January 2016 in the First People′s Hospital of Xinxiang City.Among the patients,there were 16 cases of poor response after initial induction of chemotherapy(double induction group),15 cases of first induction failure(first induction failure group) and 24 cases of relapsed and refractory AML(relapsed-refractory group).All the patients were treated with fludarabine combined with medium dose cytarabine,four weeks was a course,and after treated for two courses the therapeutic effect and survival status of the patients in the three groups were compared.Results The total effective rate in the double induction group,the first induction failure group and the relapsed-refractory group was 81.3%(13/16),66.7%(10/15) and 33.3%(8/24),respectively;the total effective rate in the double induction group and the first induction failure group was significantly higher than that in the relapsed-refractory group(χ2=8.839,4.127;P<0.05),but there was no significant difference in the total effective rate between the double induction group and the first induction failure group(χ2=0.860,P>0.05).The median of disease-free survival time in the double induction group,the first induction failure group and the relapsed-refractory group was 29,21 and 10 months,respectively.The disease-free survival time in the double induction group was significantly longer than that in the first induction failure group and the relapsed-refractory group(χ2=9.536,33.256;P<0.05),and the disease-free survival time in the first induction failure group was significantly longer than that in the relapsed-refractory group(χ2=21.077,P<0.05).The median overall survival time in the double induction group,the first induction failure group and the relapsed-refractory group was 40,29 and 12 months,respectively.The median overall survival time in the double induction group and the first induction failure group was significantly longer than that in the relapsed-refractory group(χ2=33.686,28.649;P<0.05),but there was no significant difference in the median overall survival time between the double induction group and the first induction failure group(χ2=2.417,P>0.05).Conclusion Fludarabine combined with medium dose cytarabine in the treatment of AML can obtain significant curative effect,and the effect in the patients with poor response after initial induction and the first induction failure is better than that in the patients with relapsed and refractory AML.

参考文献/References:

[1] 曾巧慧,檀卫平,麦友刚,等.不同分型急性髓系白血病患儿骨髓细胞miR-125b表达的意义[J].中华实用儿科临床杂志,2016,31(15):1148-1151.
[2] ARBER D,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[3] 张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:131-134.
[4] 沈树红.儿童急性髓细胞白血病诊断治疗进展[J].中华实用儿科临床杂志,2016,31(3):165-171.
[5] 周莉,陆勤,芮耀耀,等.儿童急性早幼粒细胞白血病临床治疗评估[J].中华实用儿科临床杂志,2016,31(15):1160-1162.
[6] 李园,秘营昌.双诱导化疗和时间序贯化疗治疗成人急性髓系白血病[J].国际输血及血液学杂志,2008,31(6):520-523.
[7] 中华医学会血液学分会白血病学组.急性髓系白血病治疗的专家共识:第一部分[J].中华血液学杂志,2009,30(6):429-431.
[8] 中华医学会血液学分会.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南:2011年版[J].中华血液学杂志,2011,32(11):804-807.
[9] 中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南:2017年版[J].中华血液学杂志,2017,38(3):177-182.
[10] GRIFFIN P,KONRIJI R,SWEET K,et al.Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy:analysis from a large,single institution experience[J].Am J Hematol,2017,92(3):232-237.
[11] 王敏芳,韩阳利,陈超华.标准及预激方案序贯双诱导治疗初治急性髓系白血病临床观察[J].临床医学,2012,32(8):26-27.
[12] WEI S,MI Y,WEI H,et al.Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapse[J].Mol Clin Oncol,2016,4(2):285-289.
[13] 王书红,于力,王全顺,等.FLAG方案治疗初次诱导失败的急性髓系白血病的疗效观察[J].中国实验血液学杂志,2007,15(6):1297-1299.
[14] 尹俊杰,梁波,王继芳,等.阿柔比星为基础的联合化学治疗方案治疗成人初治急性髓系白血病疗效观察[J].新乡医学院学报,2017,34(1):72-75.
[15] 辛柳燕,雎春芳,钟思思,等.FLAG方案治疗难治复发性急性白血病的临床疗效观察[J].赣南医学院学报,2017,37(1):58-61.

相似文献/References:

[1]牛新青,赵媛英.急性白血病患者抗凝血酶Ⅲ活性观察[J].新乡医学院学报,1991,8(04):268.
[2]王晓红,王勋伟,王岩,等.急性白血病并发多系统器官功能衰竭的危险因素[J].新乡医学院学报,1995,12(01):039.
[3]李民英,武国胜,王敏芳,等.急性白血病化疗药物体外敏感试验及I临床意义[J].新乡医学院学报,2001,18(03):189.
[4]张婧婧,张楠,王侠,等.急性髓系白血病四色流式细胞术免疫学分型特点分析[J].新乡医学院学报,2011,28(03):323.
[5]陆亚岚,陈世明,汪玉芳,等.老年急性白血病患者染色体核型异常与 FAB分型及预后的关系[J].新乡医学院学报,2015,32(09):844.
[6]崔珊珊,李雅慧,赵晨瑾,等.二甲双胍对人急性髓系白血病KG1a细胞增殖和凋亡的影响及其机制[J].新乡医学院学报,2021,38(10):901.[doi:10.7683/xxyxyxb.2021.10.001]
 CUI Shanshan,LI Yahui,ZHAO Chenjin,et al.Effect and mechanism of metformin on proliferation and apoptosis of human acute myeloid leukemia KG1a cells[J].Journal of Xinxiang Medical University,2021,38(3):901.[doi:10.7683/xxyxyxb.2021.10.001]
[7]赵小强,吴雅莉,仝佳音,等.鱼藤素对急性髓系白血病KG-1a细胞增殖和凋亡的影响及机制[J].新乡医学院学报,2021,38(12):1121.[doi:10.7683/xxyxyxb.2021.12.003]
 ZHAO Xiaoqiang,WU Yali,TONG Jiayin,et al.Effect of deguelin on the proliferation and apoptosis of acute myeloid leukemia KG-1a cells and its mechanism[J].Journal of Xinxiang Medical University,2021,38(3):1121.[doi:10.7683/xxyxyxb.2021.12.003]
[8]张彦平,刘蒙蒙,展新荣.地西他滨联合小剂量高三尖杉酯碱和阿糖胞苷治疗老年急性髓系白血病疗效观察[J].新乡医学院学报,2020,37(11):1068.[doi:10.7683/xxyxyxb.2020.11.014]
 ZHANG Yanping,LIU Mengmeng,ZHAN Xinrong.Effect of decitabine combined with low-dose homoharringtonine and cytarabine in the treatment of elderly patients with acute myeloid leukemia[J].Journal of Xinxiang Medical University,2020,37(3):1068.[doi:10.7683/xxyxyxb.2020.11.014]
[9]申清云,高 大.老年急性髓系白血病的治疗方法研究进展[J].新乡医学院学报,2019,36(1):096.[doi:10.7683/xxyxyxb.2019.01.022]
[10]张彦平,刘蒙蒙,展新荣.地西他滨联合三氧化二砷治疗老年急性髓系白血病的疗效及安全性[J].新乡医学院学报,2019,36(12):1163.[doi:10.7683/xxyxyxb.2019.12.015]
 ZHANG Yan-ping,LIU Meng-meng,ZHAN Xin-rong.Evaluation of the efficacy and safety of decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia[J].Journal of Xinxiang Medical University,2019,36(3):1163.[doi:10.7683/xxyxyxb.2019.12.015]

更新日期/Last Update: 2018-03-05